 dose/continu infus schedul fludarabin phosphat chronic lymphocyt leukemia dose/continu infus schedul fludarabin phosphat patient chronic lymphocyt leukemia cll patient evid activ diseas major rai stage patient assess respons partial respons stabl diseas thirteen respond rai stage fludarabin therapi patient stage rate pretreat stage iii IV patient final rai II surviv stage iii IV patient undergon splenectomi therapi like myelosuppress primari toxic cumul sever leukopenia thrombocytopenia infrequ sever death earli cycl treatment nonhematolog toxic mild seriou neurotox infect common minor major fatal episod fludarabin phosphat altern dose schedul effect refractori advanc cll major patient